Rafel announces Phase 3 Trappsol Cyclo failed primary endpoint but meets others
Rafael Holdings disclosed that Trappsol Cyclo failed its primary endpoint in a pivotal NPC study despite positive prespecified subgroup results, resulting in a potential delay to the 2026 NDA submission.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed